RxDoctor Payments Data

Steven Yong, MD

Cardiovascular Disease · Houston, TXNPI 1306945787

Payments from drug & device makers

$656in general payments, 2019–2025

Across 44 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$187
  • Boston Scientific$156
  • Amgen$84
  • Novo Nordisk$60
  • Boehringer Ingelheim$53
  • Bayer$40
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$59090%
  • Education$6610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amarin Pharma, Inc.21$187
Boston Scientific7$156
Amgen5$84
Novo Nordisk2$60
Boehringer Ingelheim2$53
Bayer2$40
Novartis2$37
AstraZeneca1$14
Bardy Diagnostics, Inc.1$13
Johnson & Johnson1$11

How this compares

$656 in reported general payments places this provider in the 20th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$363,921
Medicare patients
605
Services billed
3,567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban270$317,137
JardianceEmpagliflozin152$192,899
FarxigaDapagliflozin Propanediol133$158,488
VascepaIcosapent Ethyl138$123,363
EntrestoSacubitril/Valsartan80$121,896
CamzyosMavacamten13$107,032
XareltoRivaroxaban104$91,326
Repatha SureclickEvolocumab36$30,701
LivaloPitavastatin Calcium48$30,209
Icosapent Ethyl44$17,605
LinzessLinaclotide12$15,032
Rosuvastatin Calcium786$9,362
Ranolazine ErRanolazine25$6,112
Metoprolol Succinate383$4,918
Ezetimibe227$4,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$53$192,899152 claims
AstraZenecaFarxiga$14$158,488133 claims
NovartisEntresto$37$121,89680 claims
Johnson & JohnsonXarelto$11$91,326104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →